Ways2Well review

Ways2Well's premise is the right one for this category: treatment should follow bloodwork, and the compounded prescription should come from a pharmacy the company actually owns rather than an anonymous partner. It names that pharmacy, ReviveRX. Its peptide page is built around goals (weight loss, recovery, muscle, longevity, cognition and sexual health) rather than named molecules, and it is open about the first step: a $99, 20-minute consult with a licensed clinician, with any peptides that are prescribed billed separately. What it does not show is which peptides it prescribes or what they cost, so you learn both at the consult.

Ways2Well is a lab-based telehealth and longevity membership founded by Brigham Buhler, built around comprehensive blood panels and biomarker tracking, with its own patient app. Beyond peptides it covers hormone optimization, compounded GLP-1 therapy for weight loss, stem-cell and regenerative services, and IV therapy. Its compounded prescriptions are filled by ReviveRX, a named sister compounding pharmacy — an ownership relationship rather than a supplier one, which is rare disclosure. A separate storefront sells oral supplements and lab panels.

A membership with labs at the front, which is a meaningfully different starting point from a five-question quiz. The proposition is that a comprehensive panel establishes baseline biomarkers, a clinician builds a protocol against them, and follow-up testing tracks the response — for growth-hormone secretagogues in particular, that is the right sequence, since IGF-1 is the measurable variable and prescribing without it is guesswork. Owning the dispensing pharmacy is the second structural argument: it removes a markup layer and puts accountability for the preparation inside the same company that wrote the prescription. Both are genuine. What you can see before booking is the process rather than the product: the peptide page lists goals, a covered-state grid and the consult fee, but no molecule, dose or price. Its online shop sells supplements and lab tests, not peptides, which are prescribed only through the consult. The peptide page publishes its states (43 plus DC) and notes that some peptides are restricted in certain states, with California, Nevada and Ohio residents limited to weight-loss peptides.

Only the first step is priced. The peptide consult is $99 for 20 minutes with a licensed clinician, and the site is explicit that this buys the clinician's judgment, not product: any peptides prescribed are billed separately. What those peptides cost is not on the public site, and neither is whether they are sold on their own or only inside a care plan. Third-party directories circulate a figure for its GLP-1 line that we could not confirm on the company's own site, so we don't repeat it. Before booking, ask for the monthly cost of the specific peptide you want, whether it requires a care plan, and what the plan and its initial lab panel cost. The lab-first model means your first bills are likely the consult and testing, not medication.

Compounded; not FDA-approved. Prescription required only if a licensed provider finds it appropriate. Compounded sterile products are not reviewed by the FDA for purity and potency the way approved drugs are, though a company-owned pharmacy at least means the preparation and the prescription sit under one accountable entity rather than two. On the evidence, the peptides usually prescribed for these goals span the full range, and a clinic offering one is not an endorsement of it. Sermorelin, CJC-1295 with ipamorelin, and tesamorelin all act on the growth-hormone axis: real, well-described mechanisms with thin long-term human outcome data, and tesamorelin's approval is narrow — HIV-associated lipodystrophy specifically — so other uses are off-label. BPC-157 has no controlled human outcome trials at all; its tendon, gut and tissue-repair reputation rests on rodent work, and it is among the compounds the FDA has placed in a restricted category. GHK-Cu likewise has essentially no controlled human outcome data behind its collagen and skin claims. Bloodwork improves the prescribing decision; it does not upgrade the evidence for the molecule. Individual results vary.